Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
University of Pennsylvania · Inserm · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
162
total citations
- FWCI
- 41.38
- Percentile
- 100%
- References
- 48
Citations per year
Authors
35- SBStephen BagleyCorresponding
University of Pennsylvania
- ZAZev A. Binder
University of Pennsylvania
- LLLamia Lamrani
Inserm, Université Paris Sciences et Lettres, Immunité et Cancer, Parker Institute for Cancer Immunotherapy, Institut Curie
- EMEliana Marinari
University of Geneva, University Hospital of Geneva, Swiss Cancer Center Léman
- ADArati Desai
University of Pennsylvania
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Tolerability
- Medicine
- Chimeric antigen receptor
- Internal medicine
- Oncology
- Immunotherapy
- Epidermal growth factor receptor
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.